Table 3_A real−world pharmacovigilance study of FDA Adverse Event Reporting System events for pralsetinib.xlsx
Background<p>Pralsetinib, a selective oral inhibitor of rearranged during transfection (RET) fusion proteins and oncogenic RET mutants, has shown significant efficacy in treating RET fusion-positive non-small cell lung cancer and thyroid cancer. However, since pralsetinib was approved in the U...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , |
| Published: |
2024
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|